Clinical Trial: Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110194) titled 'Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies' on July 31.

Brief Summary: The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: CD20-positive Hematological Malignancies

Intervention: DRUG: TQB2825 Injection (Subcutaneous Injection)

TQB2825 is a Cluster of Differentiation 3 x Cluster of Differentiation 20 (CD3xCD20) dual antibody, which can simultaneously ...